Fruquintinib and Serplulimab Combination Therapy for First-line Treatment of Non-clear Cell Renal Cell Carcinoma: A Prospective Multicenter Study

Condition:   First-line Treatment of Non-clear Renal Cell Carcinoma Intervention:   Drug: Fruquintinib combined with Serplulimab Sponsors:   RenJi Hospital;   Shanghai Zhongshan Hospital Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials